Department of Hematology, Medical University of Lodz, 93-510 Lodz, Ul. Ciolkowskiego 2, Poland and Copernicus Memorial Hospital, 93-510 Lodz, Ul. Ciolkowskiego 2, Poland.
Future Oncol. 2013 Jan;9(1):69-91. doi: 10.2217/fon.12.157.
Monoclonal antibodies (mAbs) - rituximab, ofatumumab and alemtuzumab - have been approved for use in the therapy of chronic lymphocytic leukemia (CLL). Recently, a new generation of anti-CD20 mAbs has become available for preclinical studies and clinical trials. These antibodies were engineered to have augmented antitumor activity by increasing complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and Fc-binding affinity for the low-affinity variants of the Fcγ receptor IIIa. The most promising mAb directed against CD20 is obinutuzumab (GA-101). mAbs directed against CD22, CD37 and CD40 have also shown some activity in CLL. In addition, small modular immunopharmaceuticals - TRU-015 (anti-CD20) and TRU-016 (anti-CD37) - that retain Fc-mediated effector functions have been developed and investigated in preclinical studies and clinical trials. Antibody-drug conjugates and recombinant immunotoxins are also being evaluated in lymphoid malignancies. Further studies will elucidate the role of these agents in the treatment of CLL.
单克隆抗体（mAbs）-利妥昔单抗、奥法妥木单抗和阿仑单抗-已被批准用于治疗慢性淋巴细胞白血病（CLL）。最近，新一代抗 CD20 mAbs 已可用于临床前研究和临床试验。这些抗体经过工程改造，通过增加补体依赖性细胞毒性、抗体依赖性细胞毒性和 Fc 与 Fcγ 受体 IIIa 的低亲和力变体的结合亲和力，增强了抗肿瘤活性。针对 CD20 最有前途的 mAb 是奥滨尤妥珠单抗（GA-101）。针对 CD22、CD37 和 CD40 的 mAb 在 CLL 中也显示出一些活性。此外，小分子免疫药物 - TRU-015（抗 CD20）和 TRU-016（抗 CD37）-保留了 Fc 介导的效应功能，已在临床前研究和临床试验中进行了开发和研究。抗体药物偶联物和重组免疫毒素也在评估用于治疗淋巴恶性肿瘤。进一步的研究将阐明这些药物在治疗 CLL 中的作用。
